Cancer
A recent trial has revealed that the popular anti-diabetic and obesity drug semaglutide may have an additional benefit for people with obesity, with the potential to restore the functions of cells that attack cancer. Conducted by a team of Irish researchers, the small trial investigated whether semaglutide, developed by Novo
Cancer
Researchers from the University of Hong Kong have made significant progress in the management of liver cancer, specifically hepatocellular carcinoma (HCC), a major public health burden in Hong Kong. The study, published in Clinical and Molecular Hepatology, showcases the local guidelines and real-life practice on HCC management in Hong Kong.
Cancer
A team of researchers from Nanjing University has made a significant discovery in cancer immunotherapy, finding that inhibition of the BRD4 protein induces mismatch repair deficiency (dMMR) in a subset of cancers. This finding could lead to the development of new strategies to enhance the effectiveness of immune checkpoint blockade
Cancer
According to the latest research from the Medical University of Warsaw, the combination of immunotherapy and targeted therapy is revolutionizing the treatment of kidney cancer. Investigators have found that the combination of cabozantinib and nivolumab, a type of immunotherapy, is more effective than other drug combinations in treating advanced renal
Cancer
A groundbreaking study published in Technology in Cancer Research & Treatment has made significant strides in the treatment of gastric cancer, with researchers from Shanghai University of Traditional Chinese Medicine exploring innovative immunotherapy approaches. Key Takeaways: * Gastric cancer is one of the most common gastrointestinal tract cancers worldwide, with high
Cancer
Researchers applied single-nucleus RNA sequencing and spatial transcriptomics to identify potential therapeutic targets in brain metastases from patients with renal cell carcinoma. The study found that brain metastases had distinct gene expression programs, lower antitumor immune cell infiltration, and unique interactions with the brain microenvironment. These findings suggest that brain
Cancer
Researchers at Washington State University have recently published a review highlighting the current status of liposomes in cancer therapy. The study emphasizes the potential of liposomes as effective drug delivery systems for treating various cancers, but also acknowledges their limitations and translational challenges. According to the researchers, liposomes have been
Cancer
Researchers at Dr. M.G.R. Educational and Research Institute in Chennai, India, have made significant breakthroughs in cancer gene therapy, leveraging nanotechnology and phytochemicals to enhance treatment efficacy. Their study focuses on harnessing the potential of naturally occurring compounds, such as curcumin and resveratrol, to combat cancer growth and
Cancer
Researchers at the Fred Hutchinson Cancer Research Center have made significant findings in the treatment of multiple myeloma. Autologous stem cell transplantation (ASCT) with subsequent lenalidomide maintenance is standard therapy for multiple myeloma, but patients often relapse. The study found that TIGIT, a potent inhibitor of myeloma-specific immunity, can be
Cancer
Researchers from the University of Ottawa have investigated the impact of DNA damage response (DDR) gene alterations on the prognosis and treatment outcomes of metastatic prostate cancer (mPC) patients. The study enrolled 169 patients with DDR-a, who were compared to 48 patients without DDR-a (DDR-p). The primary endpoint was overall
Cancer
A breakthrough in cancer gene therapy has been reported, showing potential in treating glioblastoma multiforme, a malignant brain tumor with a poor prognosis. Researchers from Shahid Beheshti University of Medical Sciences in Tehran, Iran, conducted a case study involving a 37-year-old patient with two evident foci of glioblastoma multiforme. The
Cancer
Patients with urothelial bladder cancer who are ineligible for cisplatin or have unresectable disease have limited treatment options. Researchers from Pennsylvania State University (Penn State) Cancer Institute aimed to evaluate the safety and efficacy of durvalumab (durva) and radiation therapy (RT) in combination with adjuvant durva in localized urothelial cancer
